ProstatilenПростатилен
A prostate-tissue-derived polypeptide preparation with historical urological clinical reports. It is distinct from the synthetic short peptide Prostamax.
What the studies found
Randomized study in people · 2022
Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation
- Sperm DNA fragmentation after course 1
- Median 10.23% (IQR 8.12–17.90) with Prostatilen AC.Lower than placebo by the reported rank test.p = 0.000022 between groups
- Sperm DNA fragmentation after course 2
- Median 6.91% (IQR 4.91–11.30) after two active courses.14.56% (IQR 13.96–16.50) after placebo then an active course.p = 0.00004 between groups
- Seminal plasma antiradical activity
- Reported between-group difference of +6.72% after course 1 and +23.7% after course 2.p = 0.02 and p = 0.0049, respectively
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
More reported outcomes
- Adverse events and PSA
- 12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen.
Study notes · methods, sources and limitations
Participants or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
Design Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.
Important limitations
- Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course. The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.
Experimental and Clinical Pharmacology. 2022;85(2):11–15. · Original journal report
Observational study · 2018
Prostatilen AC: three-month sperm DNA fragmentation follow-up
- Mean sperm DNA fragmentation
- 17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline.
- Men with fragmentation above 30%
- 6/35 at baseline, 5/35 at month 1, 6/35 at month 2 and 6/35 at month 3.Table 2 reports no significant early change in this subgroup.
Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.
Study notes · methods, sources and limitations
Participants or model 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
Design Two 10-day courses of daily rectal Prostatilen AC, 20 days apart, without other assigned medication. The paper describes the 30 mg prostate-extract formulation with 100 mg L-arginine and 23 mg zinc supplied by the zinc complex. Sperm chromatin structure was assessed by flow cytometry before and after treatment.
Important limitations
- There was no concurrent comparison group. The authors used a laboratory outcome, and the study leaves pregnancy and live birth outcomes unanswered. The same group published a 25-person study in 2017 using a similar schedule and eligibility criteria. The extent of recruitment overlap is unclear.
- The abstract and Table 1 give different p-value thresholds for the one-month result. The table values are used here.
Andrology and Genital Surgery. 2018;19(2):52–57. · Original journal report
Animal research · 2024
Kim’s five-peptide animal comparison: tables missing
Study of multiple preparations
- Comparative preparations
- Cortexin, Pineamin, Prostatilen, Thymalin and ThymogenChapter 6.4 title. Thymogen is a defined dipeptide; the five entries are not all tissue extracts.
- Five-agent effect estimates
- Original comparative tables not recoveredNo verified head-to-head result for Pineamin versus Cortexin, Thymalin, Thymogen or Prostatilen.
Named comparator in Chapter 6.4; original per-preparation outcomes are unavailable.
Study notes · methods, sources and limitations
Participants or model Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
Design Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
Important limitations
- No established human environmental-performance result.
- The 1990s Biorhythmology and Rang-97 records were reanalyzed; they are not new human recruits. The 2022–2024 physiology studies were separate. The conclusions do not provide numerical comparisons between the five preparations. The accessible account associates HIF-1α and TSPO measurements with stress physiology and discusses the nonpeptide DMAE derivative separately; a Pineamin-mediated biomarker mechanism is not established.
- This is a documented animal comparison with inaccessible efficacy tables. Existing Pineamin reproductive studies establish a separate clinical setting, not evidence for physical performance or environmental resilience.
Kirov Military Medical Academy doctoral dissertation, 359 pp.; 2024 bibliography, related catalog entry dated 2025 · Dissertation
About Prostatilen
Names in this research collection
Prostate polypeptide complex
More study findings
Randomized study in people · 2023
Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility
- Progressive sperm motility
- 29.2% to 37.1% with the combination28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alonep < 0.01 for the greater change with combination
- Sperm DNA fragmentation
- 20.8% to 7.4% with the combination20.0% to 8.3% with laser and 21.2% to 9.8% with Prostatilen AC alonep < 0.05 for the greater change with combination
- Adverse effects
- The authors reported none during treatment or follow-up.
At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).
Study notes · methods, sources and limitations
Participants or model 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
Design Ten infrared laser sessions on alternate days. Prostatilen AC arms received 30 mg prostate extract plus 180 mg zinc arginyl glycinate rectally at bedtime for 10 days, with a repeat course after five days. Follow-up was two months after treatment.
Important limitations
- All three groups received active treatment at one center. The report leaves masking unclear. The follow-up focused on semen and hormone measures. The degree of participant overlap with earlier reports from the group is unclear.
Urology Herald. 2023;11(2):99–109. · Original journal report
Animal research · 2018
Original hypoxia, heat and cold results
Study of multiple preparations
- Prostatilen · course hypoxia
- 7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min salineAt 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed.0.1 mg/kg time p<0.01 as marked
- Publication overlap
- 2014 Table 11 and 2018 Table 1 repeat the same valuesCounts as one reported experiment. Both publications also describe a distinct acute mouse screen.
The 2014 and 2018 course-hypoxia tables repeat the same experiment.
Study notes · methods, sources and limitations
Participants or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Design The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.
Important limitations
- Separate mouse and rat protocols. Human performance was not assessed.
- The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph. Short survival in an extreme animal model is separate from human endurance or safety.
- The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.
Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Comparison in people · 2014
Single intranasal exposure at simulated altitude
Study of multiple preparations
- Prostatilen · number of complaints
- 0.2±0.2 vs 1.4±0.5Small short-term comparison.p<0.05 versus saline
Table 12 compares four small peptide arms with saline at 4,500 m.
Study notes · methods, sources and limitations
Participants or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Design Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.
Important limitations
- Participant overlap with the broader aerospace archive remains unresolved.
- Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
- The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.
Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Comparison in people · 1997
Cheprasov’s Medilab peptide comparisons in aerospace stress
Study of multiple preparations
- Hypobaric comparison
- Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measuresAbstract narrative; full arm-level estimates unavailable.
- Coriolis motion tolerance
- Cortexin +89%, Thymogen +73%, Epithalamin +68%Reported tolerance-time improvement relative to control, ten per arm.
- Sustained work
- Author reported recovery of selected Thymogen-group measures to baseline by three hoursFour per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
More reported outcomes
- Postflight respiratory infections
- 1 of 4 in Thymogen arm versus 4 of 4 salineReported during the following year, a descriptive count from four pairs.
- Program headcount
- 328 stated; stage rows add to 338The 116 and 8 are subseries, with no additional headcount contributed to the historical tally.
Study notes · methods, sources and limitations
Participants or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Design Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.
- Reported study exposure
- Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.
Important limitations
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications. The 47 modeling experts were outside the participant table.
- The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.
Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
Performance research in context
- Compound class
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Clinical reports linked; see study-specific limitations
Study methods
Original reports separated from narrative reviews and patents
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Observational study · 2018
Prostatilen AC: three-month sperm DNA fragmentation follow-up
Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.
Mean sperm DNA fragmentation · 17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3 · Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline.
Study notes and original source
Prostatilen AC: three-month sperm DNA fragmentation follow-up
Prostatilen AC rectal suppositories with prostate extract and zinc arginyl glycinate · Original journal report
S. Yu. Borovets, M. A. Rybalov, A. G. Gorbachev, S. Kh. Al-Shukri, A. V. Levina · Andrology and Genital Surgery. 2018;19(2):52–57.
Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.
Results and tables
Reported findings and study design
Two 10-day courses of daily rectal Prostatilen AC, 20 days apart, without other assigned medication. The paper describes the 30 mg prostate-extract formulation with 100 mg L-arginine and 23 mg zinc supplied by the zinc complex. Sperm chromatin structure was assessed by flow cytometry before and after treatment.
Population or model 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean sperm DNA fragmentation | 17.8 ± 6.7% at baseline, 7.5 ± 4.2% at month 1, 10.2 ± 4.1% at month 2 and 16.2 ± 4.3% at month 3 | Table 1 reports p < 0.001, p < 0.05 and p ≥ 0.05, respectively, for each follow-up versus baseline. |
| Men with fragmentation above 30% | 6/35 at baseline, 5/35 at month 1, 6/35 at month 2 and 6/35 at month 3. | Table 2 reports no significant early change in this subgroup. |
The abstract and Table 1 give different p-value thresholds for the one-month result. The table values are used here.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
- Source reviewed
- Original Russian full article, methods and Tables 1–2.
Study limitations
- There was no concurrent comparison group. The authors used a laboratory outcome, and the study leaves pregnancy and live birth outcomes unanswered.
- The same group published a 25-person study in 2017 using a similar schedule and eligibility criteria. The extent of recruitment overlap is unclear.
Reviewed 2026-11-16.
Randomized study in people · 2022
Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
Sperm DNA fragmentation after course 1 · Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. · Lower than placebo by the reported rank test. · p = 0.000022 between groups
Study notes and original source
Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Prostatilen AC, 30 mg prostate extract plus 180 mg zinc arginyl glycinate per suppository · Original journal report
I. B. Yakovlev, S. V. Teplykh, M. A. Rybalov, S. Yu. Borovets, V. B. Vasilyuk, M. V. Faraponova, A. A. Krasnov, S. V. Petlenko, V. A. Apryatina · Experimental and Clinical Pharmacology. 2022;85(2):11–15.
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
Results and tables
Reported findings and study design
Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.
Population or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sperm DNA fragmentation after course 1 | Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. | Lower than placebo by the reported rank test. · p = 0.000022 between groups |
| Sperm DNA fragmentation after course 2 | Median 6.91% (IQR 4.91–11.30) after two active courses. | 14.56% (IQR 13.96–16.50) after placebo then an active course. · p = 0.00004 between groups |
| Seminal plasma antiradical activity | Reported between-group difference of +6.72% after course 1 and +23.7% after course 2. | p = 0.02 and p = 0.0049, respectively |
| Adverse events and PSA | 12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen. |
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
- Source reviewed
- Original journal PDF, recruitment, treatment sequence, adverse events and Figures 1–3.
Study limitations
- Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course.
- The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.
Reviewed 2026-11-16.
Randomized study in people · 2023
Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility
At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).
Study notes and original source
Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility
Prostatilen AC rectal suppositories, alone or with low-intensity infrared laser · Original journal report
M. K. Potapova, S. Yu. Borovets, S. Kh. Al-Shukri · Urology Herald. 2023;11(2):99–109.
At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).
Results and tables
Reported findings and study design
Ten infrared laser sessions on alternate days. Prostatilen AC arms received 30 mg prostate extract plus 180 mg zinc arginyl glycinate rectally at bedtime for 10 days, with a repeat course after five days. Follow-up was two months after treatment.
Population or model 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Progressive sperm motility | 29.2% to 37.1% with the combination | 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone · p < 0.01 for the greater change with combination |
| Sperm DNA fragmentation | 20.8% to 7.4% with the combination | 20.0% to 8.3% with laser and 21.2% to 9.8% with Prostatilen AC alone · p < 0.05 for the greater change with combination |
| Adverse effects | The authors reported none during treatment or follow-up. |
Mean semen measures at baseline and two months
| Measure | Laser (34) | Prostatilen AC (31) | Laser and Prostatilen AC (32) |
|---|---|---|---|
| Concentration (million/mL) | 50.9 → 53.2 | 47.1 → 52.1 | 49.8 → 56.4 |
| Progressive motility (%) | 28.6 → 33.3 | 31.8 → 36.4 | 29.2 → 37.1 |
| Morphologically normal forms (%) | 2.9 → 3.5 | 3.1 → 3.9 | 2.8 → 3.6 |
| Sperm DNA fragmentation (%) | 20.0 → 8.3 | 21.2 → 9.8 | 20.8 → 7.4 |
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
- Source reviewed
- Original full article, methods, results and Figures 2–4. The matching conference abstract describes the same trial.
Study limitations
- All three groups received active treatment at one center. The report leaves masking unclear.
- The follow-up focused on semen and hormone measures. The degree of participant overlap with earlier reports from the group is unclear.
Reviewed 2026-11-16.
Animal research · 2018
Thymogen and four peptide preparations in hypoxia, heat and cold
The 2014 and 2018 course-hypoxia tables repeat the same experiment.
Study notes and original source
Thymogen and four peptide preparations in hypoxia, heat and cold
· Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Format: Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177. · Reviewed: Reported methods, results and evidence limitations
E. B. Shustov, M. T. Gasanov, G. D. Kapanadze, Yu. V. Fokin, V. S. Novikov, E. L. Matveenko, Kh. Kh. Semenov · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
Results and tables
Reported findings and study design
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
The single-dose mouse screen used 10,000 m, 8–10 per dose in the 2018 report (6–10 in the 2014 book). Table 1 instead reports a three-day rat series tested at 11,500 m the next day. Arm sizes for the repeated-dose table are not stated in the audited passage.
Population or model Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
Dose, route and schedule
Historical animal protocol. Intraperitoneal dosing daily for three days for the course hypoxia series. Thymogen 0.001, 0.01 or 0.1 mg/kg, with distinct dose ranges for the other preparations.
Protocol source ↗ · Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymogen · course hypoxia | 10.6±3.2, 20.1±11.1 and 28.6±11.8 min | At 0.001, 0.01 and 0.1 mg/kg respectively. Saline 2.2±0.1 min. · p<0.05, p<0.01 and p<0.01 versus saline as marked. |
| Thymalin · course hypoxia | 7.1±2.6 min at 0.1 mg/kg versus 2.2±0.1 min saline | 0.5 mg/kg arm was unmarked for significance. · p<0.05 for 0.1 mg/kg |
| Cortexin · course hypoxia and heat | 5.2±3.2 min at 1 mg/kg in hypoxia; 88.6±2.4 vs 96.5±5.2 min at 5 mg/kg in heat | Separate stress experiments and different doses. The heat endpoint shortened. · Both selected contrasts p<0.05 as marked |
| Prostatilen · course hypoxia | 7.0±5.6 min at 0.1 mg/kg versus 2.2±0.1 min saline | At 0.5 mg/kg: 4.2±0.7 min and a 66% increase in resistant animals as printed. · 0.1 mg/kg time p<0.01 as marked |
| Epithalamin · course hypoxia and cold | 7.4±4.5 min at 10 mg/kg in hypoxia; 194±22 vs 168±12 min at 0.5 mg/kg in air cooling | Separate dose and stress protocols. 1 mg/kg hypoxia arm was unmarked. · Both selected contrasts p<0.05 as marked |
| Thymogen · air cooling | 185±25 vs 168±12 min to rectal temperature of 35°C | 0.05 mg/kg versus control. No significant contrast marked. |
| Publication overlap | 2014 Table 11 and 2018 Table 1 repeat the same values | Counts as one reported experiment. Both publications also describe a distinct acute mouse screen. |
Matched course-hypoxia data · 2014 Table 11 and 2018 Table 1
| Arm | Dose (mg/kg unless noted) | Time (min) | Reported change (%) | Resistant-animal share increase (%) |
|---|---|---|---|---|
| Saline | 1.0 as printed | 2.2±0.1 | 0 | 0 |
| Thymalin | 0.1 | 7.1±2.6* | 238 | 38 |
| Thymalin | 0.5 | 3.7±1.0 | 76 | 16 |
| Thymalin | 1.0 | 4.4±2.2* | 110 | 16 |
| Cortexin | 0.1 | 3.9±1.4 | 86 | 5 |
| Cortexin | 0.5 | 3.8±0.4* | 81 | 16 |
| Cortexin | 1.0 | 5.2±3.2* | 148 | 5 |
| Prostatilen | 0.1 | 7.0±5.6** | 233 | 0 |
| Prostatilen | 0.5 | 4.2±0.7* | 100 | 66* |
| Prostatilen | 1.0 | 2.4±1.0 | 14 | 16 |
| Epithalamin | 0.1 | 2.7±0.6 | 22 | 15 |
| Epithalamin | 1.0 | 1.8±0.5 | 0 | 0 |
| Epithalamin | 10.0 | 7.4±4.5* | 236 | 33 |
| Thymogen | 0.001 | 10.6±3.2* | 405 | 48* |
| Thymogen | 0.01 | 20.1±11.1** | 857 | 60* |
| Thymogen | 0.1 | 28.6±11.8** | 1262 | 80** |
M±m. * p<0.05, ** p<0.01 versus saline. Percentage column transcribed as printed and may differ from calculations using rounded means. The book’s adjacent mouse protocol describes the acute screen.
The papers distinguish the single-dose mouse screen from the three-day rat protocol. The matching table adds no independent animals or human participants.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
- Source reviewed
- Original 2018 methods and Tables 1–3 compared with Volume III Chapter 7, pp. 174–177.
Study limitations
- The 2018 rat course results and 2014 book table belong to one evidence family. The book omits an explicit course-series species and altitude in the adjacent paragraph.
- Short survival in an extreme animal model is separate from human endurance or safety.
Reviewed 2026-11-09.
Comparison in people · 2014
Four intranasal peptide arms at simulated 4,500 m
Table 12 compares four small peptide arms with saline at 4,500 m.
Study notes and original source
Four intranasal peptide arms at simulated 4,500 m
· Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Format: Original publication and selected methods and results checked · Reviewed: Reported methods, results and evidence limitations
N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
Results and tables
Reported findings and study design
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.
Population or model Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Dose, route and schedule
Single intranasal administration one hour before ascent: Thymogen 1 µg, Cortexin 10 mg, Epithalamin 10 mg or Prostatilen 5 mg. The control received equivalent-volume saline.
Protocol source ↗ · Original publication and selected methods and results checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymogen · blood lactate | 1.81±0.21 vs 2.98±0.46 | Source Table 12 units not specified on the row. · p<0.05 versus saline |
| Cortexin · complex visuomotor reaction latency | 423±12 vs 381±9 ms | Slower response, even with some favorable markers. · p<0.01 versus saline |
| Epithalamin · number of complaints | 0.33±0.13 vs 1.4±0.5 | Authors marked a trend. · p<0.1 versus saline |
| Prostatilen · number of complaints | 0.2±0.2 vs 1.4±0.5 | Small short-term comparison. · p<0.05 versus saline |
The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
- Source reviewed
- Original publication and selected methods and results checked
Study limitations
- Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
Reviewed 2026-11-09.
Comparison in people · 1997
Cheprasov’s Medilab peptide comparisons in aerospace stress
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Study notes and original source
Cheprasov’s Medilab peptide comparisons in aerospace stress
· Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations
V. V. Cheprasov · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Results and tables
Reported findings and study design
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Hypobaric test: three arms of 10 at 5,000 m for 60 min. Motion: seven arms of 10 in a Coriolis test. Work: four arms of four at 50% of individually tolerated load. Postflight: four mission pairs, one participant per pair given Thymogen.
Population or model 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
Dose, route and schedule
Hypoxia: intranasal Cortexin or Thymalin, 20 mg per course over two days, or placebo. Motion: single intranasal 5 mg Thymalin, Cortexin, Prostatilen or Epithalamin, or 50 µg Thymogen, with oral scopolamine 0.1 mg and placebo controls. Work: nasal Thymogen 100 µg or Cortexin 10 mg before work and after 6 and 12 h, or oral sydnocarb plus Bemitil, or saline. Postflight: intranasal Thymogen 100 µg/day for seven days.
Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Hypobaric comparison | Thymalin: 15–20% higher work measures; Cortexin: 10–15% improvement in selected operator measures | Abstract narrative; full arm-level estimates unavailable. |
| Coriolis motion tolerance | Cortexin +89%, Thymogen +73%, Epithalamin +68% | Reported tolerance-time improvement relative to control, ten per arm. |
| Sustained work | Author reported recovery of selected Thymogen-group measures to baseline by three hours | Four per arm. Cortexin and oral Bemitil plus sydnocarb were separate comparators. |
| Postflight respiratory infections | 1 of 4 in Thymogen arm versus 4 of 4 saline | Reported during the following year, a descriptive count from four pairs. |
| Program headcount | 328 stated; stage rows add to 338 | The 116 and 8 are subseries, with no additional headcount contributed to the historical tally. |
The aerospace findings concern separate stress and recovery tasks, with no reliable pooled treatment effect.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- 116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
- Source reviewed
- Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
- Small comparisons, incomplete outcome reporting and unclear separation from related Medilab publications.
- The 47 modeling experts were outside the participant table.
Reviewed 2026-11-09.
Animal research · 2024
Kim’s five-peptide comparison in animal stress experiments
Named comparator in Chapter 6.4; original per-preparation outcomes are unavailable.
Study notes and original source
Kim’s five-peptide comparison in animal stress experiments
· Dissertation
Format: Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable · Reviewed: Reported methods, results and evidence limitations
A. E. Kim · Kirov Military Medical Academy doctoral dissertation, 359 pp.; 2024 bibliography, related catalog entry dated 2025
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
Results and tables
Reported findings and study design
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
Population or model Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
Protocol information
Peptide doses, routes, group assignments and timing require Chapter 6.4. The separate 25 mg/kg DMAE derivative was not Pineamin or another peptide.
Protocol source ↗ · Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Comparative preparations | Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen | Chapter 6.4 title. Thymogen is a defined dipeptide; the five entries are not all tissue extracts. |
| Pineamin · animal stress models | Author highlights resistance to hypoxia, heat and cold | Selected conclusions only; dose, sample sizes, numerical results and ranking unavailable. |
| Five-agent effect estimates | Original comparative tables not recovered | No verified head-to-head result for Pineamin versus Cortexin, Thymalin, Thymogen or Prostatilen. |
| HIF-1α and TSPO | Predictive-marker hypothesis; peptide-specific causal data unavailable | The DMAE derivatives were evaluated in separate nonpeptide groups. |
| Document acquisition | 49-page dissertation abstract with tables cataloged in 2024 | Find the original author abstract and Chapter 6.4 before updating any ranking. |
This is a documented animal comparison with inaccessible efficacy tables. Existing Pineamin reproductive studies establish a separate clinical setting, not evidence for physical performance or environmental resilience.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
- Source reviewed
- Dissertation catalog, Chapter 6.4 heading, methods summary and conclusions; 49-page author abstract cataloged but not retrieved; original comparison tables unavailable
Study limitations
- The 1990s Biorhythmology and Rang-97 records were reanalyzed; they are not new human recruits. The 2022–2024 physiology studies were separate.
- The conclusions do not provide numerical comparisons between the five preparations.
- The accessible account associates HIF-1α and TSPO measurements with stress physiology and discusses the nonpeptide DMAE derivative separately; a Pineamin-mediated biomarker mechanism is not established.
Reviewed 2026-11-08.
Experiment described in a patent · 1996
Prostatilen: smooth-muscle use claims — RU2058780C1
Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.
Favorable conservative-treatment outcome · 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic care · Patent-defined decision about unscheduled surgery · After inpatient conservative care
Study notes and original source
Prostatilen: smooth-muscle use claims — RU2058780C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
В.Х. Хавинсон, С.В. Серый, А.Л. Кожемякин, Р.И. Валеев · RU2058780C1 · patent family 20132424
Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.
Results and tables
Reported patent results
Reported findings
Prostatilen-containing care had more reported favorable short-term prostate outcomes, with no verified randomization.
Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.
Population or model Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Favorable conservative-treatment outcome | 15/28 (54%) with Prostatilen versus 9/52 (17.3%) with symptomatic care | Patent-defined decision about unscheduled surgery · After inpatient conservative care |
| Residual urine ≤100 mL subgroup | 11/11 favorable outcomes versus 7/19 in controls | Small, potentially selected subgroups |
| Incontinence series | Near-complete cessation of involuntary urination in 17/23; sphincter-tone normalization in 15/23 | Separate uncontrolled series, not part of the 28-versus-52 comparison |
Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Each cohort has its own response rate.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent reports include a 23-patient incontinence series and a separate prostate-adenoma comparison: 28 adjunctively treated versus 52 symptomatic-care patients.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The preparation is a tissue-derived complex; these claims do not establish equivalence to a defined synthetic prostate peptide.
- Concurrent treatment, nonrandom allocation and short-term clinical decisions prevent a reliable comparative efficacy estimate. Each cohort has its own response rate.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Lab research · 2015
[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].
Prostatilen was among the calf-tissue preparations tested in corresponding rat organotypic cultures. The abstract reports tissue-growth and marker changes across the preparations; it does not provide a separate numerical effect estimate for this preparation.
Study notes and original source
[POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS].
· Original journal report
Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN · Advances in gerontology = Uspekhi gerontologii · PMID 26390619
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
- Population / setting
- Organotypic tissue cultures from young and old rats
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- Tissue-culture growth is not organ regeneration in patients; equivalence to current branded products is unverified.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Review of earlier studies · 2013
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
Study notes and original source
Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results
Khavinson VKh, Kuznik BI, Ryzhak GA · Adv Gerontol 26(1):20-37. PMID 24003726
Summarizes clinical work on seven named peptide preparations. Useful for tracing original Russian reports and distinguishing tissue extracts from short peptides.
- Population / setting
- Originating group’s clinical and gerontology literature
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Review by investigators in the originating program; not independent replication.
- Clinical findings must be traced to the exact preparation and original study.
Reviewed 2026-09-29.
Observational study · 1991
The use of prostatilen in treating patients with chronic prostatitis
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
Study notes and original source
The use of prostatilen in treating patients with chronic prostatitis
Tkachuk VN, Gorbachev AG, Khavinson VKh · Urol Nefrol (Mosk) (6):40-43. PMID 1823682
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
Results and tables
Reported findings and study design
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
307 patients aged 18–74; disease duration 4 months–36 years; assessments at treatment completion and 4–6 months later.
Dose, route and schedule
Prostatilen: 5–10 mg intramuscularly once daily for five to ten days.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported symptom response | 96.7% | Disappearance or attenuation; uncontrolled composite clinical response |
| Onset of response | After 2–3 injections; greatest reported response after 5–6 | Descriptive clinical observation |
| Studied regimen | 5–10 mg intramuscularly daily for 5–10 days | |
| Participants | 307 |
The abstract does not give a placebo response, a validated symptom-score change or separate response rates at each follow-up. Its claim of no side effects is not a systematic incidence estimate.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 307 men with chronic prostatitis
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- The abstract does not establish a randomized concurrent control.
- Reported tolerability cannot establish long-term safety; findings do not apply to Prostamax.
Reviewed 2026-11-01.
Observational study · 1991
The use of prostatilen in treating patients with prostatic diseases
Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.
Study notes and original source
The use of prostatilen in treating patients with prostatic diseases
Vozianov AF, Gorpinchenko II, Boĭko NI, Drannik GN, Khavinson VKh · Urol Nefrol (Mosk) (6):43-46. PMID 1823683
Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.
Results and tables
Reported findings and study design
Prostatilen clinical report: 37 patients with chronic prostatitis and 15 with prostatic adenoma.
Population or model 37 patients with chronic prostatitis and 15 with prostatic adenoma
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Symptoms, uroflow and semen measures | Changes reported | Numerical outcome values and comparator data absent |
| Adverse reactions | None reported in this small study |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 37 patients with chronic prostatitis and 15 with prostatic adenoma
- Source reviewed
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
- Small mixed clinical groups; control methods and adverse-event ascertainment unclear from the abstract.
- The tissue extract is not the synthetic peptide Prostamax.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗